Illumina Stock Slides 5.53 Percent on Analyst Downgrade

genomeweb
360dx

Illumina Stock Slides 5.53 Percent on Analyst Downgrade

Jun 10, 2005

NEW YORK, June 10 (GenomeWeb News) - Shares in Illumina were down 5.53 percent, or $.67, at $11.45 in mid-afternoon trading after an investment bank downgraded the company's stock.

To read the full story....

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Sweet Wormwood Genome Provides Clues for Boosting Production of Antimalarial Compound
VC Aspire Universal Forms Personalized Medicine Investment Fund
Freenome, Biognosys Partner on Early Cancer Detection
Loss-of-Function, Truncating Variants in UK Biobank Data Point to New Drug Targets
MDxHealth Q1 Revenues Up 50 Percent
Waters Q1 Revenues Up 7 Percent

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

Main menu